Cargando…
Combination of Ablation and Immunotherapy for Hepatocellular Carcinoma: Where We Are and Where to Go
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and is increasing in incidence. Local ablative therapy plays a leading role in HCC treatment. Radiofrequency (RFA) is one of the first-line therapies for early local ablation. Other local ablation techniques...
Autores principales: | Wang, Kunpeng, Wang, Cong, Jiang, Hao, Zhang, Yaqiong, Lin, Weidong, Mo, Jinggang, Jin, Chong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714655/ https://www.ncbi.nlm.nih.gov/pubmed/34975896 http://dx.doi.org/10.3389/fimmu.2021.792781 |
Ejemplares similares
-
Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going?
por: Jang, Albert, et al.
Publicado: (2021) -
Combination immunotherapy: Where do we go from here?
por: Overacre, Abigail E., et al.
Publicado: (2015) -
Diabetic cardiomyopathy: where we are and where we are going
por: Lee, Wang-Soo, et al.
Publicado: (2017) -
The Clusmy Child: Where Are We and Where Are We Going?
por: Hadders-Algra, Mijna, et al.
Publicado: (2003) -
European HEPnet: where we are and where we are going
por: Carpenter, B E, et al.
Publicado: (1990)